Stay updated on BGB324 with Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the BGB324 with Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the BGB324 with Pembrolizumab in Melanoma Clinical Trial page
- CheckyesterdayChange DetectedMelanoma and MedlinePlus Genetics were added under Related topics, expanding the page with additional disease context and genetics resources for users.SummaryDifference0.2%

- Check8 days agoNo Change Detected
- Check16 days agoChange DetectedThe page now reflects an updated ClinicalTrials.gov interface revision (v3.5.3) and the related generic topic/link section text was refreshed (with “Melanoma”/“related topics” and a prior revision reference removed). This represents a platform/content wrapper update rather than a change to the study record itself.SummaryDifference0.2%

- Check23 days agoChange DetectedAdded Melanoma and MedlinePlus Genetics as related topics; updated page revision from v3.5.0 to v3.5.2.SummaryDifference0.2%

- Check44 days agoChange DetectedMelanoma-related topics and the MedlinePlus Genetics related links were removed from the page's related topics section.SummaryDifference0.2%

- Check52 days agoChange DetectedAdded Melanoma and related topics, including MedlinePlus Genetics, and updated the site revision from v3.4.3 to v3.5.0.SummaryDifference0.2%

- Check59 days agoChange Detected- Revision metadata updated: added Revision: v3.4.3. The Melanoma label and the MedlinePlus Genetics topic were removed, and Revision: v3.4.2 was deleted.SummaryDifference0.2%

Stay in the know with updates to BGB324 with Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BGB324 with Pembrolizumab in Melanoma Clinical Trial page.